Moreover, recent investigations have also found mild hyperbilirubinemia that can be induced by either enhancement of HO activity or partial inhibition of UGT1A1, which has therapeutic potential for delaying CKD progression and improving cardiovascular outcomes in this patient population. Here, UGT1A1 is linked to Hyperbilirubinemia.